This 48-year-old man knew he was at risk — three first-degree relatives had had heart attacks and diabetes. He walked in at 210 pounds with a BMI of 31 — the lowest threshold the medical system calls obesity. What he didn't know was that his triglycerides were over 700, his blood pressure was already high, and his coronary arteries already showed calcium buildup (a marker of blockage). Three years later, the picture had been rewritten.
DM
Case by Douglas Maready, MD
Three-year outcome
19%
sustained body weight loss. Hypertension, hypertriglyceridemia, and prediabetes all resolved — and an antihypertensive medication was never needed.
−73%
Triglycerides 700+ → 187 mg/dL
−22
Systolic BP 142 → 120 mmHg
−24
ALT (liver enzyme) 49 → 25
+59%
HDL (good cholesterol) 22 → 35 mg/dL
Anonymized patient case · 48 yo M · 2022–2026
Core Concepts
Six pieces of the picture worth slowing down for.
Each card opens a quick-reference summary with the clinical detail behind that part of the case — what we found, how we thought about it, and what the literature says.
01
BMI 31 — Already in Trouble
Class 1 obesity, the mildest category. But the rest of his markers proved this wasn't mild.
Read pearls
02
A Family History, But Not Destiny
Father with heart attack, diabetes, and hypertension. Grandfather with heart attack. Mother with ovarian cancer. The genetics were already loaded.
Read pearls
03
Triglycerides Over 700
At this level, the lipid panel becomes a medical issue of its own — pancreatitis is the immediate risk, atherosclerosis is the long one.
Read pearls
04
Coronary Calcium at 47
A CAC score of 2 in the LAD before age 50 reframes the conversation from "prevention" to active disease.
Read pearls
05
Why the BP Med Was Never Started
His blood pressure was elevated. We chose to treat the disease underneath it first — and never had to come back to an antihypertensive.
Read pearls
06
Three Years Later
The weight has held. Most of the cardiometabolic disease is gone. Two numbers — HDL and LDL — still need attention.
Read pearls
Case Walkthrough
Two deeper looks at the case.
The full visit-by-visit timeline, and the clinical lessons this case teaches about treating mild obesity in a high-risk patient.
Three-Year Treatment Timeline
From initial presentation through three years of maintenance — weights, vitals, labs, and the decisions that drove each visit.
Open walkthrough
What This Case Teaches
Five clinical lessons about mild-category obesity, the risk that hides inside it, and what changes when you treat the disease underneath.
Open walkthrough
About this case
This is a teaching case based on a real patient seen in Dr. Maready's medical weight management practice between 2022 and 2026. Identifying details have been removed; the clinical course, lab values, vital signs, and treatment decisions are unchanged.
This page is an educational summary, not medical advice. Decisions about your own care should be made with your clinician based on your individual history, exam, and labs. References throughout the page link to peer-reviewed primary literature and current guidelines.
Case Study / Three-Year Treatment Timeline
Case Walkthrough
Three-Year Treatment Timeline
From first visit through three years of maintenance — every weight, vital, and lab inflection point, and the decisions that drove each visit. Click any visit to expand.
Weight over 3 years
Pounds · each marker is a clinic visit · x-axis to scale by date
Phase 1 · Initial Presentation & Saxenda
01Dec 2022 — Initial Visit
+
Vitals: Weight 210 lb, BMI 31, BP 142/98 (untreated).
Labs: Triglycerides >700 mg/dL, HDL 22 mg/dL, LDL elevated, ALT 49, A1c in prediabetic range.
Imaging: Coronary calcium score = 2 (all in the LAD).
Plan: Treat obesity as the upstream driver. Started Saxenda (liraglutide), titrated to 3 mg daily. Deliberately deferred starting an antihypertensive pending response.
02Apr 3, 2023 — 4 Months on Saxenda 3 mg
+
Vitals: Weight 192 lb (BMI 28.8), BP 108/60.
Weight loss: −18 lb / 8% TWL.
Labs: Triglycerides dropped from >700 to the mid-180s. LDL went up (classic pattern as TG clears). HDL improved.
Decision: Saxenda was tolerated well at maximal dose, but lipid normalization wasn't complete. Switched to Wegovy (semaglutide) for greater weight-loss potency and additional metabolic benefit.
Phase 2 · Transition to Wegovy
03Late Mar 2023 — Wegovy Initiated
+
Started Wegovy at 1 mg weekly with planned monthly titration through 1.7 mg to the maintenance dose of 2.4 mg.
04Jul 11, 2023 — 7 Months In, on Wegovy 2.4 mg
+
Vitals: Weight 179 lb (BMI 26.84), BP 118/70. Snoring resolved. Tolerating Wegovy 2.4 mg without GI side effects.
Weight loss: −40 lb / 19% TWL — the threshold he has held since.
All cardiometabolic diagnoses noted as resolved or in remission on the chart, with the comment "Resolved w/ Wegovy and lifestyle changes." Wegovy continued long-term as maintenance.
Phase 3 · Maintenance
06Jun 13, 2024 — Lab Review
+
Vitals: Weight 163.3 lb (BMI 24.47), BP 108/70 — lowest weight of the entire course.
Vitals: Weight 168–172 lb (BMI 25.17–25.77) across the two fall visits, BP 120/76 to 124/84.
Labs: LDL 123, HDL 35, A1c 5.2%.
Plan: Continued Wegovy 2.4 mg.
Timeline synthesis
Treatment ran in three phases: the first 12-month period of weight loss and metabolic remission and then ongoing treatment afterwards with the disease in remission and lifestyle stabilizing, and an ongoing maintenance phase where the focus has shifted from weight to fine-tuning lipids and cardiac monitoring. The arc shows what's possible when obesity is treated as the primary disease, long term — and what still requires attention even when the headline number is good.
Case Study / What This Case Teaches
Teaching Points
What This Case Teaches
Five clinical lessons drawn from a single patient's three-year journey through obesity treatment. Click any lesson to expand.
01BMI alone underestimates risk in mild obesity
+
"Class 1 obesity" can sound like a borderline finding. In this patient, that label sat alongside coronary calcium, severe hypertriglyceridemia, prediabetes, and Stage 2 hypertension — all by age 47.
The takeaway: BMI is one input, not a triage tool. Lab data, family history, and imaging routinely reframe what "mild" means. Patients with BMI 30–35 and any CV risk-enhancers deserve the same urgency as patients with class 2 or 3 obesity.
02Family history is exam-room data
+
Three first-degree CV events (father with MI, T2DM, HTN; paternal grandfather with MI; mother with ovarian cancer) reframed every threshold for this patient. It didn't change his treatment plan — but it tightened the goal for every modifiable factor.
The takeaway: family history isn't decorative on the chart. Use it. With premature CHD in a first-degree relative, LDL goals get tighter, action thresholds get lower, and time to action gets shorter.
03Severe hypertriglyceridemia is metabolic disease, not a lipid problem
+
Triglycerides >700 mg/dL warned of pancreatitis risk and signaled the broader insulin-resistant phenotype. Treatment with a fibrate or omega-3 might have lowered the number; treating obesity moved more numbers, faster, with one intervention.
The takeaway: when triglycerides are this high in a patient with obesity, the obesity treatment is also the lipid treatment. Layering specific lipid drugs early can become unnecessary.
04"Treat the disease underneath" outperforms layering medications
+
This patient came in with five active diagnoses (obesity, hyperlipidemia, hypertension, prediabetes, family-hx CHD). The temptation in primary care is to treat each one separately — an antihypertensive, a statin, metformin, fibrate. Instead, the obesity was treated as the upstream cause; four of those five diagnoses moved into remission as a consequence.
The takeaway: when you can identify a single upstream driver, addressing it can collapse the medication list. He never started an antihypertensive. He never started metformin. He may still need a statin, but the rest of his cardiometabolic disease is in remission on a single agent.
05Maintenance is the next chapter, not the conclusion
+
Three years in, the headlines look excellent. The fine print is more interesting: HDL has come up from a low baseline but isn't yet at goal. LDL is borderline given his CAC and family history; medication is in consideration. Wegovy continues as long-term therapy — cessation would risk re-activating the original disease.
The takeaway: a successful obesity treatment course doesn't end with the weight target. The maintenance phase has its own clinical agenda — lipid fine-tuning, vascular surveillance, and ongoing pharmacotherapy support.
Final synthesis
A single patient case doesn't establish a treatment regimen — but it can illustrate, vividly, what's possible when mild-category obesity is treated as the upstream disease that it is. This case is a working example of obesity medicine as cardiometabolic risk reduction, not weight loss as cosmetic outcome.